ETS2 and neoplasm: Chemotherapy triggers TECs to suppress IGFBP7, and the upregulation of IGF1 activates the FGF4-FGFR1-ETS2 pathway in TECs and accelerates the conversion of tumor cells to chemoresistant tumor stem-like cells [105].